Finance

Beta
Lists
VXRT:OTCMKTS
Vaxart Inc
$0.62
+0.52%
(+0.0032) 1D
Jun 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VXRT...
Open
$0.62
High
$0.62
Low
$0.59
Mkt. cap
149.24M
Avg. vol.
452.40K
Volume
295.81K
P/E ratio
4.04
52-wk high
$0.84
52-wk low
$0.26
EPS
$0.15
Beta
1.10
Shares outstanding
242.04M
No. of employees
65
Open
$0.62
High
$0.62
Low
$0.59
Mkt. cap
149.24M
Avg. vol.
452.40K
Volume
295.81K
P/E ratio
4.04
52-wk high
$0.84
52-wk low
$0.26
EPS
$0.15
Beta
1.10
Shares outstanding
242.04M
No. of employees
65
News stories
From sources across the web
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc. Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEO-
Employees65
FoundedMar 2004
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitevaxart.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
39.73M
72.41M
104.24M
39.23M
Cost of goods sold
49.74M
75.95M
45.15M
29.41M
Cost of revenue
49.74M
75.95M
45.15M
29.41M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.60M
4.28M
3.67M
4.64M
Operating expense
4.60M
4.28M
3.67M
4.64M
Total operating expenses
54.33M
80.22M
48.82M
34.05M
Operating income
-14.60M
-7.81M
55.42M
5.17M
Other non operating income
-1.00K
-7.00K
-35.00K
-11.00K
EBT including unusual items
-14.97M
-8.12M
55.39M
5.21M
EBT excluding unusual items
-14.97M
-8.12M
55.39M
5.21M
Income tax expense
20.00K
17.00K
344.00K
29.00K
Effective tax rate
-0.13%
-0.21%
0.62%
0.56%
Other operating expenses
-
-
-
-
Net income
-14.99M
-8.14M
55.04M
5.18M
Net profit margin
-37.72%
-11.24%
52.81%
13.20%
Earnings per share
-0.07
-0.04
0.24
-
Interest and investment income
310.00K
302.00K
547.00K
551.00K
Interest expense
-672.00K
-608.00K
-546.00K
-505.00K
Net interest expenses
-362.00K
-306.00K
1.00K
46.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.41M
-5.73M
57.48M
6.30M
Gain or loss from assets sale
-
5.00K
33.00K
10.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer